2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. ADC Payload
  5. Auristatin Isoform

Auristatin

Auristatins are synthetic analogs of dolastatin 10 that function as highly potent microtubule-disrupting cytotoxins and are widely used as payloads in antibody-drug conjugates (ADCs) for targeted cancer therapy[1][2]. Auristatin derivatives, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF), inhibit tubulin polymerization, disrupt microtubule dynamics, and induce mitotic arrest, thereby suppressing tumor cell proliferation[1][3]. Mechanistically, structural studies demonstrate that auristatins destabilize microtubules through direct interaction with the tubulin network, providing the molecular basis for their antimitotic activity[1]. In cancer models, the extreme potency of auristatins necessitates targeted delivery strategies, and ADC platforms exploit antibody-mediated internalization to release auristatin payloads selectively within tumor cells[2][4]. Compared with related microtubule-targeting payload classes such as maytansinoids, auristatins remain among the most frequently deployed ADC warheads because of their high cytotoxic activity at low intracellular concentrations[4]. Distinctions between major auristatin isoforms are also relevant for experimental design, as MMAE and MMAF differ in physicochemical properties and cellular behavior despite sharing a common microtubule-directed mechanism[3]. For research applications, auristatin-based ADCs serve as established tools for investigating targeted cytotoxic delivery, microtubule biology, therapeutic resistance, and payload optimization in oncology models[2][3][4].

Auristatin Related Products (15):

Cat. No. Product Name Effect Purity
  • HY-15162
    Monomethyl auristatin E
    		99.98%
    Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.
  • HY-15579
    MMAF
    		99.97%
    MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A.
  • HY-15162A
    MMAE-d8
    		99.29%
    MMAE-d8 is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor.
  • HY-15582
    Auristatin E
    		99.86%
    Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids.
  • HY-12522
    PF-06380101
    		99.95%
    PF-06380101 (Aur0101), an auristatin microtubule inhibitor, is a cytotoxic Dolastatin 10 analogue. PF-06380101 (Aur0101) shows excellent potencies in tumor cell proliferation assays and differential ADME properties when compared to other synthetic auristatin analogues that are used in the preparation of ADCs.
  • HY-79256
    MMAF-OMe
    		99.62%
    MMAF-Ome, an antitubulin agent, is also an ADC cytotoxin. MMAF-Ome inhibits several tumor cell lines with IC50s of 0.056 nM, 0.166 nM, 0.183 nM, and 0.449 nM for MDAMB435/5T4, MDAMB361DYT2, MDAMB468, and Raji (5T4-) cell lines, respectively.
  • HY-15579A
    MMAF hydrochloride
    		99.97%
    MMAF (Monomethylauristatin F) hydrochloride is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A.
  • HY-15580
    Dolastatin 10
    		98.34%
    Dolastatin 10 (DLS 10) is a potent antimitotic peptide that inhibits tubulin polymerization.
  • HY-78933
    Fmoc-MMAE
    		99.35%
    Fmoc-MMAE is a protective group-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Fmoc-MMAE can be used in the synthesis of ADC.
  • HY-15581
    MMAD
    		99.92%
    MMAD is a potent tubulin inhibitor, is a toxin payload in antibody agent conjugates (ADCs).
  • HY-15579B
    MMAF sodium
    		99.59%
    MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A.
  • HY-15579AS
    MMAF-d8 hydrochloride
    		99.52%
    MMAF-d8 (hydrochloride)e is a deuterated form of MMAF hydrochloride, which is a microtubule disrupting agent.
  • HY-12522S
    PF-06380101-d8
    		99.27%
    PF-06380101-d8 (Aur0101-d8) is a deuterium labeled PF-06380101 (HY-12522). PF-06380101, an Auristatin microtubule inhibitor, is a cytotoxic Dolastatin 10 analogue.
  • HY-P1126
    Dolastatin 15
    Dolastatin 15 (DLS 15), a depsipeptide derived from Dolabella auricularia, is a potent antimitotic agent structurally related to the antitubulin agent Dolastatin 10. Dolastatin 15 induces cell cycle arrest and apoptosis in multiple myeloma cells. Dolastatin 15 can be used as an ADC cytotoxin.
  • HY-15581S
    MMAD-d8
    		98.95%
    MMAD-d8D is a deuterated form of MMAD, which is a microtubule disrupting agent.